The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...

the first allogeneic engineered Type 1 Treg (Tr1) cell therapy to enter the clinic. We are also bullish on the highly differentiated profile of TRX319, our allogeneic CD19 CAR-Treg, given its ...

Founded by leading scientists who discovered Tr1 cells, Tr1X develops off-the-shelf, allogeneic Treg and CAR-Treg therapies engineered for superior safety, scalability and accessibility ...

Founded by leading scientists who discovered Tr1 cells, Tr1X develops off-the-shelf, allogeneic Treg and CAR-Treg therapies engineered for superior safety, scalability and accessibility ...